RxDoctor Payments Data

David Murphy, MD

Pulmonary Disease · Sequim, WANPI 1184695041

Payments from drug & device makers

$494in general payments, 2019–2025

Across 16 payments — averaging $30.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$146
  • Calyxo, Inc.$105
  • Regeneron Healthcare Solutions, Inc.$81
  • GSK$68
  • Merck$38
  • Rochester Medical Corporation$30
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$25652%
  • Education$23848%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC2$146
Calyxo, Inc.3$105
Regeneron Healthcare Solutions, Inc.1$81
GSK4$68
Merck2$38
Rochester Medical Corporation2$30
Teleflex LLC1$15
AstraZeneca1$12

How this compares

$494 in reported general payments places this provider in the 55th percentile of 275 pulmonary disease providers in Washington.

See all pulmonary disease providers in Washington

Medicare billing

Part B allowed, 2024
$189,342
Medicare patients
1,182
Services billed
3,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab54$231,665
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$200,503
Spiriva RespimatTiotropium Bromide76$87,066
Stiolto RespimatTiotropium Br/Olodaterol Hcl57$66,744
Advair HfaFluticasone Propion/Salmeterol98$59,340
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr58$46,913
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$32,749
Breo ElliptaFluticasone/Vilanterol32$27,737
SymbicortBudesonide/Formoterol Fumarate61$27,384
Incruse ElliptaUmeclidinium Bromide46$26,597
Spiriva HandihalerTiotropium Bromide21$19,386
XareltoRivaroxaban20$18,608
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate38$12,187
EliquisApixaban13$9,827
Albuterol Sulfate HfaAlbuterol Sulfate171$9,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$68$305,705293 claims
AstraZenecaBreztri Aerosphere, Symbicort$12$60,13286 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 275 pulmonary disease providers in Washington.

Other pulmonary disease in Sequim

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →